Navega Therapeutics

Navega is a preclinical company developing a gene therapy that is injected into the patient’s spine. This results in a protein binding to and turning off one place in the genome; this is the same place that is mutated in the genome of humans that feel no pain. Our technology achieves this in a way that is non-permanent and more specific than other approaches by delivering CRISPR/dCas9 or zinc-fingers fused to a repressor via adeno-associated viruses (AAVs) to target epigenetic repression of NaV1.7.